Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)

22. oktober 2026 oppdatert av: GlaxoSmithKline

A Phase 3, Randomized, Multicenter, Open-Label Study of Velzatinib (GSK6042981) Versus Imatinib in Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST)

Gastrointestinal Stromal Tumour (GIST) is a soft tissue tumour that develops in the digestive system, most often in the stomach or small intestine. It is caused by changes in certain proteins that cause the cells to grow uncontrollably. Although current treatments may be effective, tumours may stop responding over time, highlighting the need for newer options. This study is evaluating velzatinib (GSK6042981) in participants with newly diagnosed GIST that has spread or cannot be surgically removed. Velzatinib will be compared with imatinib, the standard treatment, to assess whether it can delay disease worsening and is safe and well tolerated.

Studieoversikt

Status

Rekruttering

Studietype

Intervensjonell

Registrering (Antatt)

800

Fase

  • Fase 3

Utvidet tilgang

Tilgjengelig utenfor den kliniske utprøvingen. Se utvidet tilgangspost.

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

      • Buenos Aires, Argentina, 1425
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Mariano Dioca
      • Capital Federal, Argentina, C1426ANZ
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Yanina Pfluger
      • Ciudad Autonoma de Buenos Aire, Argentina, C1414DRK
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Guillermo Mendez
      • Ciudad Autonoma de Buenos Aire, Argentina, C1431FWO
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Julieta Grasselli
      • Ciudad autOnoma de Bueno, Argentina, C1419AHN
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Samanta Straminsky
      • San Miguel de Tucumán, Argentina, T4000IHE
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ruben Segovia
    • Victoria
      • Melbourne, Victoria, Australia, 3004
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • John Zalcberg
      • Barretos, Brasil, 14784-400
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Arinilda Bragagnoli
      • Florianópolis, Brasil, 88034-000
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ana Paula Stramosk
      • Natal, Brasil, 59075-740
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Sulene Oliveira
      • Porto Alegre, Brasil, 90020-090
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Andreas Lutz
      • Vitória, Brasil, 29043-260
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • GLAUCIO BERTOLLO
    • Piauí
      • Teresina, Piauí, Brasil, 64002-530
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Welligton Figueiredo
    • Ontario
      • Toronto, Ontario, Canada, M5G 2M9
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Albiruni Abdul Razak
    • Quebec
      • Montreal, Quebec, Canada, H3A 1A1
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Jonathan Noujaim
        • Ta kontakt med:
        • Ta kontakt med:
      • Helsinki, Finland, 00029
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Sari Jaamaa
    • Arizona
      • Scottsdale, Arizona, Forente stater, 85258
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Michael Gordon
        • Ta kontakt med:
        • Ta kontakt med:
    • California
      • San Francisco, California, Forente stater, 94158
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Victoria Wang
    • Connecticut
      • New Haven, Connecticut, Forente stater, 06510-3206
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Philippos Costa
    • Maryland
      • Bethesda, Maryland, Forente stater, 20817-1802
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ralph Boccia
    • Missouri
      • Kansas City, Missouri, Forente stater, 64132
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Jaswinder Singh
    • Nebraska
      • Omaha, Nebraska, Forente stater, 68130-2042
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Kirsten Leu
    • New York
      • New York, New York, Forente stater, 10065
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Ciara Kelly
        • Ta kontakt med:
        • Ta kontakt med:
    • North Carolina
      • Durham, North Carolina, Forente stater, 27710
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Juneko Grilley-Olson
        • Ta kontakt med:
        • Ta kontakt med:
    • Ohio
      • Canton, Ohio, Forente stater, 44718
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Nashat Gabrail
    • Tennessee
      • Knoxville, Tennessee, Forente stater, 37920
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Hovedetterforsker:
          • Saikrishna Gadde
        • Ta kontakt med:
    • Texas
      • Houston, Texas, Forente stater, 77030
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Hovedetterforsker:
          • Neeta Somaiah
        • Ta kontakt med:
    • Washington
      • Seattle, Washington, Forente stater, 98109-4405
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Min Park
      • Lyon, Frankrike, 69373
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Mehdi Brahmi
        • Ta kontakt med:
        • Ta kontakt med:
      • Reims, Frankrike, 51100
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Olivier Bouché
      • Thessaloniki, Hellas, 54639
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Grigorios Rallis
      • Thessaloniki, Hellas, 55535
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ioannis Boukovinas
    • Attica
      • Chaïdári, Attica, Hellas, 124 62
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Anastasios Kyriazoglou
    • Crete
      • Heraklion, Crete, Hellas, 700 13
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ioannis Souglakos
      • Milan, Italia, 20133
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Elena Rosa Fumagalli
      • Milan, Italia, 20141
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Roberta Giovanna Sanfilippo
      • Palermo, Italia
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Giuseppe Badalamenti
      • Roma, Italia, 00128
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Bruno Vincenzi
        • Ta kontakt med:
        • Ta kontakt med:
      • Ehime, Japan, 791-0280
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Tomohiro Nishina
      • Fukuoka, Japan, 812-8582
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Eiji Oki
      • Gifu, Japan, 501-1194
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Nobuhisa Matsuhashi
      • Hokkaido, Japan, 060-8648
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Yoshito Komatsu
      • Kanagawa, Japan, 241-8515
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Hiroki Osumi
      • Osaka, Japan, 565-0871
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Yukinori Kurokawa
      • Tokyo, Japan, 104-0045
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Hidekazu Hirano
      • Tokyo, Japan, 135-8550
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Masato Ozaka
      • Toyama, Japan, 930-0194
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Takayuki Ando
      • Yamaguchi, Japan, 755-8505
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Tatsuya Ioka
      • Beijing, Kina, 100141
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Jian Li
        • Ta kontakt med:
        • Ta kontakt med:
      • Chengdu, Kina, 610041
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Bo Zhang
      • Guangzhou, Kina, 510060
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Haibo Qiu
      • Guangzhou, Kina, 510655
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Yanhong Deng
        • Ta kontakt med:
        • Ta kontakt med:
      • Guangzhou, Kina, 510080
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Xinhua Zhang
      • Hangzhou, Kina, 310016
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Yu Zheng
      • Jinan, Kina, 250021
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Lei Cong
      • Nanjing, Kina
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Hao Xu
      • Shanghai, Kina, 200000
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ye Zhou
      • Shanghai, Kina, 20001
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Ming Wang
        • Ta kontakt med:
        • Ta kontakt med:
      • Wuhan, Kina, 430022
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Kai-Xiong Tao
      • Zhengzhou, Kina, 450052
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Yang Fu
      • Nijmegen, Nederland, 6525GA
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ingrid Desar
    • South Holland
      • Leiden, South Holland, Nederland, 2333 ZA
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Hans Gelderblom
        • Ta kontakt med:
        • Ta kontakt med:
      • Oslo, Norge, 0379
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Kjetil Boye
      • Warsaw, Polen, 02-781
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Piotr Rutkowski
      • BaracaldoVizcaya, Spania, 48903
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Alberto Muñoz Llarena
      • Barcelona, Spania, 8025
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Raul Teres Lleida
        • Ta kontakt med:
        • Ta kontakt med:
      • Madrid, Spania, 28046
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Virginia Martinez Marin
      • Madrid, Spania, 28034
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • María Ángeles Vaz Salgado
      • Madrid, Spania, 28040
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Nadia Hindi Muñiz
      • Madrid, Spania, 28041
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Aránzazu Manzano Fernández
      • Oviedo, Spania, 33011
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Maria del Pilar Solis Hernandez
      • Seville, Spania, 41013
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Irene Carrasco García
      • Valencia, Spania, 46009
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Hector Augusto Aguilar Andino
      • Zaragoza, Spania, 50009
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Javier Martínez Trufero
        • Ta kontakt med:
        • Ta kontakt med:
      • London, Storbritannia, SW3 6JJ
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Robin Jones
      • London, Storbritannia, NW1 2PG
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Vasilios Karavasilis
      • Newcastle upon Tyne, Storbritannia, NE7 7DN
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Anna Stansfeld
      • Sheffield, Storbritannia, S10 2SJ
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Robin Young
    • Greater Manchester
      • Manchester, Greater Manchester, Storbritannia, M20 4BX
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Alexander Lee
        • Ta kontakt med:
        • Ta kontakt med:
      • Genolier, Sveits, 1272
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Michael Montemurro
      • Uppsala, Sverige, SE-751 85
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Sharmineh Moghaddam
      • Seongnam-si Gyeonggi-do, Sør -Korea, 13620
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ji-Won Kim
      • Seoul, Sør -Korea, 03080
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Do-youn Oh
      • Seoul, Sør -Korea, 03722
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Minkyu Jung
      • Seoul, Sør -Korea, 138-736
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Min-Hee Ryu
      • Seoul, Sør -Korea, 03181
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Dong-Hoe Koo
      • Suwon Kyunggi-do, Sør -Korea, 16499
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Tae Hwan Kim
    • Seoul Teugbyeolsi
      • Seoul, Seoul Teugbyeolsi, Sør -Korea, 06351
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Jungyong Hong
      • Changhua, Taiwan, 500
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ruo-Han TSENG
      • Taichung, Taiwan, 404
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Li-Yuan Bai
        • Ta kontakt med:
        • Ta kontakt med:
      • Taipei, Taiwan, 10002
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Kun-Huei Yeh
      • Taipei, Taiwan, 112
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Chueh-Chuan Yen
      • Taoyuan, Taiwan, 33305
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Chun-Nan Yeh

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Is at least 18 years of age or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the Informed consent form (ICF).

  • Has histologically or cytologically confirmed GIST that is metastatic and/or surgically unresectable.

  • Has not received prior systemic therapy for their metastatic and/or surgically unresectable GIST.

  • Tumor tissue must be provided to the central laboratory. Tumor tissues may be archival (preferred) or obtained from a fresh biopsy acquired for standard of care (biopsies must be collected before randomization).

  • Participants must have ≥1 target lesion (TL).

  • All participants must use adequate contraception according to local regulations throughout the study and for a specified period after the last dose of study medication (at least 30 days for velzatinib/imatinib, or 15 days for imatinib only, as applicable, or longer if local regulations specify).

  • Male participants must either be abstinent or use a male condom (with a recommendation for their female partner to use highly effective contraception). They must also refrain from donating semen.

  • Female participants must not be pregnant or breastfeeding.

    1. Those of non-childbearing potential are eligible without additional contraception.
    2. Those of childbearing potential must use an acceptable, highly effective contraceptive method and have a negative pregnancy test before starting the study. The investigator will assess their pregnancy risk.
  • Is capable of giving signed informed consent as described in the protocol, including compliance with the requirements and restrictions listed in the ICF and in this protocol.

  • Has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤1.

  • Has adequate organ function.

Exclusion Criteria:

  • Has a malignancy (except disease under study) that has progressed or required active treatment within the past 24 months except for basal cell or squamous cell carcinomas of the skin or in-situ carcinomas [e.g., breast, cervix, bladder] that have been resected with no evidence of metastatic disease.

  • Has any clinically significant gastrointestinal abnormalities that may alter absorption, e.g., malabsorption syndrome or major resection of the stomach and/or bowels.

  • Has had any major surgery (minor surgical procedures such as central venous catheter placement and tumor needle biopsy are not considered major surgical procedures) within 14 days of the first dose of study treatment or participants who have not fully recovered from surgery.

  • Has any history of prior allogenic or autologous bone marrow transplant or other solid organ transplant. Participants with a history of autologous stem cell transplant are eligible for study participation provided the following eligibility criteria are met: a) transplant was [>100 days] prior to screening, and b) the participant has no active infection(s) at the time of screening.

  • Has known allergy or hypersensitivity to velzatinib or imatinib, in the opinion of the investigator or medical monitor, contraindicates participation in the study.

  • Has a history within 6 months prior of clinically significant or uncontrolled cardiac disease, unstable angina, acute myocardial infarction, New York Heart Association Class III or IV congestive heart failure [New York Heart Association,1994], or clinically significant arrhythmia not controlled by standard of care therapy, ventricular arrhythmia, cerebrovascular accident or transient ischemic attack and uncontrolled hypertension.

  • Has untreated brain or Central nervous system (CNS) metastases or brain/CNS metastases that have progressed [e.g., evidence of new or enlarging brain metastasis or new neurologic symptoms attributable to brain/CNS metastases]. Participants with previously treated and clinically stable brain/CNS metastases and who have completed all corticosteroid therapy for ≥2 weeks before randomization are not excluded from participation

  • Has ongoing adverse reaction(s) from prior therapy that has (have) not recovered to ≤Grade 1 or to the baseline status preceding prior therapy, (excluding e.g., alopecia, hearing loss, vitiligo, endocrinopathy managed with replacement therapy, and Grade 2 neuropathy) or that the investigator, with the agreement of the sponsor, considers to be not clinically relevant for the tolerability of study intervention in the current clinical study.

  • Has any active renal condition (e.g., infection, requirement for dialysis, or any other significant renal condition that could affect the participant's safety).

  • Has any serious and/or unstable medical or psychiatric disorder or other condition(s) (including laboratory assessment abnormalities) that could interfere with the participant's safety, obtainment of informed consent, or compliance to the study procedures.

  • Has received radiotherapy within 14 days prior to first dose of study treatment.

  • Has received any live vaccine within 30 days of randomization. Vaccination against Coronavirus disease 2019 (COVID-19) using vaccines that are authorized via the appropriate regulatory mechanisms (e.g., Emergency Use Authorization, Conditional Marketing Authorization, or Marketing Authorization Application) are not exclusionary.

  • Has received any transfusion of blood products (including platelets or red blood cells) or administration of colony-stimulating factors (including Granulocyte colony-stimulating factor [G-CSF], granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) within 14 days before randomization.

  • Is currently enrolled or has participated in any other clinical study involving an investigational study intervention or any other type of medical research before signing ICF.

  • Has a positive drug/alcohol screening assessment.

  • Has a known Human immunodeficiency virus (HIV) infection and meets at least one of the following criteria:

    1. Has documented evidence of plasma HIV-1 ribonucleic acid (RNA) ≥50 c/mL within 3 months prior to or at screening. In the 3 to 12 months prior to screening, plasma HIV 1 RNA levels consistently <50 c/mL are required for enrollment; if multiple instances of plasma HIV-1 RNA values ≥50 c/mL occurred in the 3 to 12 months prior to screening, the participant is not eligible for enrollment unless, per the investigator's assessment, the elevations were neither persistent nor associated with antiretroviral resistance; OR
    2. Has not had CD4 cell counts measured in the past 12 months (i.e., at least two separate measurements taken a minimum of 28 days apart, one of which must be conducted at screening); OR
    3. Has had any CD4 cell count values ≤200 cells/mm3 in the past 12 months; OR
    4. Has had one or more changes in their combination antiretroviral therapy regimen (except for switches as allowed per details provided in protocol) or has received an antiretroviral therapy regimen that is inconsistent with locally recommended guidelines during the 3 months prior to screening; OR
    5. Has a history of HIV-associated non-Hodgkin lymphoma within 5 years prior to screening or a history of HIV-associated invasive cervical cancer; OR
    6. Has received treatment with an HIV 1 immunotherapeutic vaccine within 90 days of screening.
  • Is pregnant or breastfeeding.

  • Is unable to adhere to the protocol, including requirements for the Follow-up Period of the study.

  • Has an alanine aminotransferase (ALT) value >2.5x upper limit of normal (ULN) or (for participants with documented liver metastases/tumor infiltration) has an ALT value >5x ULN

  • Has a total bilirubin value >1.5x ULN.

  • Has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice.

  • Evidence of chronic hepatitis B virus (HBV) infection with detectable viral load despite antiviral therapy with high resistance barrier.

  • 12-lead electrocardiogram (ECG) demonstrating mean QT interval corrected (QTc) corrected by Fridericia's formula >480msec at screening or history of long QT syndrome.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Imatinib

Imatinib will be administered

Andre navn:
  • GLIVEC / GLEEVEC
Eksperimentell: Velzatinib

Velzatinib will be administered

Andre navn:
  • GSK6042981

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Progression-Free Survival (PFS) as assessed by Blinded independent central review (BICR)
Tidsramme: Up to approximately 74 months

PFS is defined as time from the date of randomization to the date of disease progression or death due to any cause, whichever occurs first.

Up to approximately 74 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of participants with Treatment-emergent adverse event (TEAEs) and serious adverse event (SAEs) by severity
Tidsramme: Up to approximately 75 months
Up to approximately 75 months
Number of participants with TEAEs/SAEs leading to dose reductions, interruptions and treatment discontinuation
Tidsramme: Up to approximately 75 months
Up to approximately 75 months
Number of participants with clinically significant changes in vital signs, electrocardiograms, and clinical laboratory parameters
Tidsramme: Up to approximately 75 months
Up to approximately 75 months
Plasma concentration of velzatinib
Tidsramme: Up to approximately 75 months
Up to approximately 75 months
Confirmed Objective Response Rate (ORR) as assessed by BICR
Tidsramme: Up to approximately 75 months

Confirmed ORR is defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) per response criteria.

Up to approximately 75 months
Overall survival (OS)
Tidsramme: Up to approximately 75 months

OS is defined as the time from the date of randomization to the date of death due to any cause.

Up to approximately 75 months
Confirmed ORR as assessed by Investigator assessment
Tidsramme: Up to approximately 75 months

Confirmed ORR is defined as the percentage of participants with a confirmed CR or PR per response criteria.

Up to approximately 75 months
Time from initial study randomization to second disease progression or death (PFS2)
Tidsramme: Up to approximately 75 months

PFS2 is defined as the time from initial study randomization to second disease progression or death after starting the next line of treatment.

Up to approximately 75 months
PFS as assessed by Investigator assessment
Tidsramme: Up to approximately 75 months

PFS is defined as time from the date of randomization to the date of disease progression or death due to any cause, whichever occurs first.

Up to approximately 75 months
Time to Response (TTR)
Tidsramme: Up to approximately 75 months

TTR as assessed by BICR and investigator, is defined as time from randomization until the first documented PR or CR that was subsequently confirmed.

Up to approximately 75 months
Duration of Response (DOR)
Tidsramme: Up to approximately 75 months

DOR as assessed by BICR and investigator, is defined as time from the first documented PR or CR that was subsequently confirmed until the first documented PD or death due to any cause.

Up to approximately 75 months
Time to Second Subsequent Therapy (TSST)
Tidsramme: Up to approximately 75 months

TSST is defined as the time from the date of randomization to the earliest date of second subsequent therapy or death due to any cause.

Up to approximately 75 months
Change from baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) score
Tidsramme: Up to approximately 75 months

The EORTC QLQ-C30 includes 30-item questionnaire for evaluating the health-related quality of life (HRQoL) of participants participating in cancer clinical studies. These include functional scales, symptom scales, global health status scale, and single item scales. Scores are averaged and transformed to 0 to 100. Higher scores indicate greater functioning, better global health status, or more severe symptoms

Up to approximately 75 months
Time to confirmed deterioration (TTCD) of EORTC QLQ-C30
Tidsramme: Up to approximately 75 months

TTCD is defined as the time from the date of randomization to the first confirmed clinically meaningful deterioration on the Physical & Role Functioning & Global Health Status/QoL scales of the EORTC QLQ-C30.

Up to approximately 75 months
Number of participants with symptomatic AEs by severity as measured by patient-reported outcome Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Tidsramme: Up to approximately 75 months

The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicities in participants in cancer clinical trials. The PRO-CTCAE includes an item library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE.

Up to approximately 75 months
Number of participants with bothersome AEs/tolerability as measured by the Functional Assessment of Cancer Therapy - General (FACT-GP5)
Tidsramme: Up to approximately 75 months

The FACT GP5 is an assessment focused on the overall side effects impact to inform the tolerability of a treatment. The FACT GP5 ("I am bothered by side effects of treatment") responses are given on a 5-point Likert type scale. The response scale ranges from 0 (Not at all) to 4 (Very much). Higher scores indicate a higher degree of AE bother.

Up to approximately 75 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

27. juli 2026

Primær fullføring (Antatt)

30. august 2032

Studiet fullført (Antatt)

28. september 2032

Datoer for studieregistrering

Først innsendt

6. mai 2026

Først innsendt som oppfylte QC-kriteriene

7. mai 2026

Først lagt ut (Faktiske)

13. mai 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

23. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

22. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere